We are pleased to announce the publication of our first full scientific article in the open-access journal Biomedicine & Pharmacotherapy.
This peer-reviewed paper presents a detailed overview of the mechanism of action, selectivity, and preclinical potency of FTX-101, a rationally designed 29-amino-acid peptide that targets the NRP1/Plexin-A1 receptor complex. Through a series of in vitro experiments, the study shows how FTX-101 disrupts semaphorin 3A (Sema3A) signaling, a key inhibitor of oligodendrocyte precursor cell (OPC) recruitment and differentiation.
By neutralizing this inhibitory pathway, FTX-101 restores OPC migration and promotes maturation into myelin-producing oligodendrocytes. The peptide also demonstrated the ability to re-establish myelin sheath formation in human iPSC-derived neuron-oligodendrocyte co-cultures challenged with Sema3A, underscoring its potential as a first-in-class remyelinating agent.
This publication marks an important step in validating the scientific foundation behind FTX-101 and its development for demyelinating diseases such as multiple sclerosis and chronic optic neuropathies. With its dual mechanism of action, promoting both recruitment and maturation of oligodendrocytes, FTX-101 addresses a key unmet need in regenerative neurology.
Graphical Abstract
From the online Biomedicine & Pharmacotherapy publication
